{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Corneal tissue samples were collected to evaluate the composition of microcyst-like epithelium observed in participants treated with belantamab mafodotin.","groups":[{"description":"A superficial corneal epithelial tissue specimen was obtained by performing impression cytology (IC) procedure in participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. The procedure was only performed in one eye. Participants did not need to be on active treatment.","id":"OG000","title":"Participants Allocated to Undergo Impression Cytology Procedure"},{"description":"A superficial corneal epithelial tissue specimen was obtained by performing superficial keratectomy (SK) procedure in participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. The procedure was only performed in one eye. Participants did not need to be on active treatment.","id":"OG001","title":"Participants Allocated to Undergo Superficial Keratectomy Procedure"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"EICSK population","reportingStatus":"POSTED","timeFrame":"Up to approximately 23 months","title":"Number of Participants With Abnormality in Composition of Corneal Epithelium After Administration of Belantamab Mafodotin","type":"PRIMARY","unitOfMeasure":"Participants"}